ReviewJCO oncology practice2022
Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology.
Review in JCO oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Evaluation and Treatment Options for Abnormal Uterine Bleeding in Premenopausal Patients With a History of Breast Cancer.O&G open · 2026Review
- Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.Current treatment options in oncology · 2026Review
- Investigation of the protective effects of hesperidin against nivolumab toxicity in rat testis tissue.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Testicular Function After Immune-Checkpoint Inhibitors Treatment.Clinical endocrinology · 2025Article
- A single-institution study evaluating the fertility of young adults with malignancy treated with immunotherapy.The oncologist · 2025Article
- Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies.Human reproduction (Oxford, England) · 2025Review
- Review
- The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.Frontiers in immunology · 2025Review
- The potential role of exercise in mitigating fertility toxicity associated with immune checkpoint inhibitors (ICIs) in cancer patients.The journal of physiological sciences : JPS · 2024Review
- The Effects of Cancer Immunotherapy on Fertility: Focus on Hematological Malignancies.Biomedicines · 2024Review
- Fertility Preservation in the Era of Immuno-Oncology: Lights and Shadows.Journal of personalized medicine · 2024Review
- Molecular Mechanisms Determining Mammalian Oocyte Quality with the Treatment of Cancer Therapy.Advances in anatomy, embryology, and cell biology · 2024Review
- Review
- Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis.International journal of molecular sciences · 2022Review
- Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Immune checkpoint inhibition has resulted in significant efficacy across many cancer types, including melanoma. Melanoma is the second most common cancer among those of reproductive age, yet the reproductive toxicities of adjuvant and first-line immunotherapy are largely unknown.The normal innate and adaptive immune systems play a vital role in reproductive organ homeostasis of men and women and are essential for implantation, fertility, and a successful pregnancy. The programmed cell death-1 receptor/programmed cell death receptor ligand-1 (PD-1/PD-L1) pathway is essential in several aspects of fertility and pregnancy. Recent studies have largely focused on the role of the PD-1/PD-L1 pathway in fetomaternal tolerance, highlighting the importance of intact immune regulation in promoting a successful pregnancy.In this review, we describe a case of a reproductive-aged female with stage IIIC melanoma who sought guidance on family planning after pembrolizumab therapy. We discuss the known fertility-related toxicities of immune checkpoint inhibitors, the potential targets for reproductive toxicity in males and nonpregnant females, and the implications of anti-PD-1 therapy in relation to fetomaternal tolerance. Informed decision making will benefit from data and consensus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.